Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$60.63 USD

60.63
1,530,008

+1.91 (3.25%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $60.67 +0.04 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up

Halozyme reports better-than-expected third-quarter 2024 results. The company raises revenue guidance for 2024. Stock rises in after-hours trading.

Halozyme Therapeutics (HALO) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 28.28% and 16.97%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options

Investors need to pay close attention to Halozyme Therapeutics (HALO) stock based on the movements in the options market lately.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Why Halozyme Therapeutics (HALO) Could Beat Earnings Estimates Again

Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line

Madrigal (MDGL) posts better than expected second-quarter numbers. It adds nearly $15 million from sales of the first-ever NASH drug Rezdiffra, which is encouraging for a drug launched in April 2024.

Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up

Halozyme (HALO) reports better-than-expected second-quarter 2024 results. The company maintains revenue guidance for 2024. Stock rises in after-hours trading.

Zacks.com featured highlights include Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare

Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare have been highlighted in this Screen of The Week article.

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 16.67% and 9.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Sumit Singh headshot

4 Stocks That Flaunt an Impressive Interest Coverage Ratio

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. HALO, LDOS, ATO & ADUS are sound enough to meet financial obligations.

Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y

Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.

CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected

CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.

BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View

BioMarin (BMRN) posts better-than-expected second quarter earnings. It also raises its revenue and earnings guidance for full-year 2024.